5D3D image
Deposition Date 2015-08-06
Release Date 2015-08-19
Last Version Date 2024-05-01
Entry Detail
PDB ID:
5D3D
Keywords:
Title:
Crystal structure of Staphylococcal Superantigen-Like protein 3
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.94 Å
R-Value Free:
0.22
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Staphylococcal Superantigen-Like protein 3
Gene (Uniprot):ssl3
Chain IDs:A, B
Chain Length:195
Number of Molecules:2
Biological Source:Staphylococcus aureus (strain NCTC 8325)
Primary Citation
Structural basis for inhibition of TLR2 by staphylococcal superantigen-like protein 3 (SSL3).
Proc.Natl.Acad.Sci.USA 112 11018 11023 (2015)
PMID: 26283364 DOI: 10.1073/pnas.1502026112

Abstact

Toll-like receptors (TLRs) are crucial in innate recognition of invading micro-organisms and their subsequent clearance. Bacteria are not passive bystanders and have evolved complex evasion mechanisms. Staphylococcus aureus secretes a potent TLR2 antagonist, staphylococcal superantigen-like protein 3 (SSL3), which prevents receptor stimulation by pathogen-associated lipopeptides. Here, we present crystal structures of SSL3 and its complex with TLR2. The structure reveals that formation of the specific inhibitory complex is predominantly mediated by hydrophobic contacts between SSL3 and TLR2 and does not involve interaction of TLR2-glycans with the conserved Lewis(X) binding site of SSL3. In the complex, SSL3 partially covers the entrance to the lipopeptide binding pocket in TLR2, reducing its size by ∼50%. We show that this is sufficient to inhibit binding of agonist Pam2CSK4 effectively, yet allows SSL3 to bind to an already formed TLR2-Pam2CSK4 complex. The binding site of SSL3 overlaps those of TLR2 dimerization partners TLR1 and TLR6 extensively. Combined, our data reveal a robust dual mechanism in which SSL3 interferes with TLR2 activation at two stages: by binding to TLR2, it blocks ligand binding and thus inhibits activation. Second, by interacting with an already formed TLR2-lipopeptide complex, it prevents TLR heterodimerization and downstream signaling.

Legend

Protein

Chemical

Disease

Primary Citation of related structures